drugset / Trial / NCT03168321

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

NCT03168321

Phase 3 Completed 813 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle Lotion.

Timeline

Start
2017-06-29
Primary completion
2018-06-07
Completion
2018-06-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tazarotene Small molecule 0.045 %

Indications